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Abstract
Background: High cholesterol may be a modifiable risk factor for prostate cancer but results have been
inconsistent and subject to potential “reverse causality” where undetected disease modifies cholesterol prior to
diagnosis.
Methods: We conducted a prospective cohort study of 12,926 men who were enrolled in the Midspan studies
between 1970 and 1976 and followed up to 31st December 2007. We used Cox-Proportional Hazards Models to
evaluate the association between baseline plasma cholesterol and Gleason grade-specific prostate cancer
incidence. We excluded cancers detected within at least 5 years of cholesterol assay.
Results: 650 men developed prostate cancer in up to 37 years’ follow-up. Baseline plasma cholesterol was
positively associated with hazard of high grade (Gleason score≥8) prostate cancer incidence (n = 119). The
association was greatest among men in the 2nd highest quintile for cholesterol, 6.1 to < 6.69 mmol/l, Hazard Ratio
2.28, 95% CI 1.27 to 4.10, compared with the baseline of < 5.05 mmol/l. This association remained significant after
adjustment for body mass index, smoking and socioeconomic status.
Conclusions: Men with higher cholesterol are at greater risk of developing high-grade prostate cancer but not
overall risk of prostate cancer. Interventions to minimise metabolic risk factors may have a role in reducing
incidence of aggressive prostate cancer.
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Background
The incidence of prostate cancer has increased over sev-
eral decades such that it is now the most commonly
diagnosed cancer among men in Europe and the USA
[1,2]. There is evidence that increasing age, genetic pre-
disposition [3,4] and ethnicity [5] are risk factors for
prostate cancer while opportunistic testing may partly
explain temporal increases and international variations
in incidence [1]. Prostate cancer is about six times more
common in more developed compared to less developed
countries, suggesting that modifiable Western lifestyle
factors may have a causal role [6]. It has been observed
for about a century that the levels of cholesterol, fatty
deposits, lecithin and some other lipids in the diseased
prostate are elevated [7]. Several studies have explored
the relationship between serum cholesterol levels and
the incidence of prostate cancer and its associated mor-
tality with inconsistent conclusions [8-13]. Some found
a positive association between cholesterol and prostate
cancer mortality [8,14] while others revealed either an
inverse relationship [10,13] or no overall association
with incidence [9,11].
Three recent reports have suggested that while serum
cholesterol has no association with overall incidence of
prostate cancer, patients with low cholesterol are less
likely to have high grade (Gleason score ≥8) disease
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reproduction in any medium, provided the original work is properly cited.[15-17]. In two of these studies, follow-up was short (3.1
and 5.5 years) [16,17] and none excluded early events so
that “reverse causality"–that is, cholesterol was modified
by undiagnosed disease and not a causal factor for it–
may have partly explained their observations.
Given that age, genetics and ethnicity are not modifi-
able risk factors, the potential role of cholesterol on
prostate cancer risk may be of clinical importance. In
the present study we evaluated the association between
plasma cholesterol level and both overall and grade-spe-
cific prostate cancer incidence, using two of the Mid-
span prospective cohort studies with up to 37 years’
follow-up. Individuals diagnosed with prostate cancer
within 5 years of baseline cholesterol assay were
excluded to reduce the potential effects of “reverse
causality.”
Methods
Cohort characteristics
The Midspan studies began in the 1960s and 1970s in
Scotland, UK. Their methods have been described in
detail elsewhere [18]. We included two Midspan studies
in this research paper. The first, the Collaborative study,
was conducted on employed men and women aged
from 21 to 75 years from 27 workplaces in Glasgow,
Clydebank and Grangemouth between 1970 and 1973
[19]. The second Midspan study, the Renfrew/Paisley
study, was a general population study of residents of the
towns of Renfrew and Paisley, conducted between 1972
and 1976. All residents aged 45-64 years were invited to
take part and 80% accepted [20].
Because of the geographical proximity of the study
populations, a small number of individuals participated
in both cohorts. For individuals with more than one
record, only the earliest record was used. Study proto-
cols consisted of a self-administered questionnaire fol-
lowed by a screening examination at a specially set-up
clinic. Questions included demographic details, occupa-
tion, lifestyle habits, including smoking, and health [20].
As part of the screening examination, measurements
were made for height and weight and blood pressure. A
blood sample was obtained at baseline screening for the
measurement of total circulating plasma cholesterol.
Body mass index (BMI) was calculated from weight (in
kg) divided by height (in metres) squared and cate-
gorised according to the World Health Organisation
[21] classification in which BMI < 18.50 is underweight,
18.50 to 24.99 is the normal range, 25.00 to 29.99 is
overweight and ≥30.00 is obese. A blood sample was
obtained at baseline screening for the measurement of
total circulating plasma cholesterol [20]. Socioeconomic
status was derived from occupation according to the
relevant version of the General Register Office Classifi-
cation of Occupation [22] and graded into six categories:
I [23], II (intermediate), III (skilled non-manual), III
(skilled manual), IV (partly skilled) and V (unskilled)
[20]. Ex-smokers were defined as reporting giving up
smoking at least a year before screening, otherwise they
were defined as current smokers. Cholesterol was cate-
gorised by quintiles. Only records for male participants
were used for this study.
Follow up
Follow up for mortality was carried out by flagging Mid-
span participants with the National Health Service Cen-
tral Register. Deaths were then notified to the Midspan
team on a monthly basis. Information on cancer regis-
trations and hospital activity was obtained by linkage to
the Scottish Morbidity Records (SMR) data and was
complete from 1972 onwards [24]. Follow up began on
the date of screening to the date of cancer incidence,
date of death, date of embarkation (leaving the United
Kingdom) or the censor date of 31st December 2007,
whichever came first.
Ethical approval
The Privacy Advisory Committee of the Information
Services Division of NHS Scotland gave permission for
the linked data to be used in this study.
Risk factor and outcome definitions
Prostate cancer was defined as International Classifica-
tion of Diseases (ICD) revision 9 codes 185 and ICD-10
codes C61. Prostate cancer incidence was determined if
it was included in any cancer registration (SMR06), any
diagnosis position of an acute hospital record (SMR01)
or any position on the death record. Where a patient
had prostate cancer recorded on more than one type of
record, the earliest date was taken as time of first diag-
nosis. The Gleason grading system is a method used to
describe the morphology of clinical PC. Data on Gleason
score were available from the cancer registry (SMR06).
The Scottish Cancer Registry began recording Gleason
score from 1st January 1997 and therefore the analysis
of grade-specific associations between cholesterol and
PC was restricted to the follow up of the surviving
cohort as of 1st of January 1997 and these were just
records from SMR06.
Statistical analysis
Cox proportional hazards models were used to estimate
hazard ratios (HRs) for PC incidence from screening
and for specific histological grade from 1st January
1997. For grade specific analysis, we excluded men who
h a dd i e do rb e e nd i a g n o s e dw i t hP Cb e f o r e1
st January
1997. Separate models were run for each Gleason cate-
gory, and men with PC and other Gleason scores were
censored at their date of diagnosis. Age was taken as the
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2007. The alternative approach of using time since
screening as the timescale was also investigated [25].
The estimates presented in this study are obtained by
using age as the time scale. All analyses were conducted
using STATA version 11 (StataCorp, College Station,
TX, USA). The following covariates were included in
the multivariate model: smoking status, BMI and socioe-
conomic status and results are presented based on this
model. There is some evidence that increasing height
significantly increases the risk of developing PC, so BMI
was replaced with height in the second model and esti-
mates for height are presented when BMI was not
included in the model. There were missing data for
some covariates: 89 in socioeconomic status; 1 in height
and weight; 1 in smoking status; Total missing data for
all covariates was less than 0.01% which did not change
any of the associations when we ran the analysis both
including those observations after imputations and
excluding these individuals. We presented the final
results after imputations in which missing information
on continuous variables was replaced by the sample
mean while for categorical variables missing data were
replaced by modal values. The lowest category was used
as referent for the cholesterol and all other categorical
covariates. The analysis was repeated by combining the
two highest quintiles of cholesterol. Furthermore, analy-
sis was also carried out by using the recommended clin-
ical cut offs for adults cholesterol level, where
cholesterol level of less than 5.1 mmol/L was considered
as desirable, 5.1 to < 6.21 mmol/L as borderline high
and ≥6.21 mmol/L as high [26]. Analysis was also strati-
fied based on BMI categories (i.e. desirable, overweight,
obese), and also by using the median BMI of the sample,
consistent with an earlier study [15]. Adherence to the
proportional hazards assumption was investigated by
plotting smoothed Schoenfeld residuals against time; no
violations of the assumption were identified. All statisti-
cal tests were two tailed and statistical significance was
taken as p < 0.05. The analysis was carried out after
excluding individuals diagnosed with PC within 5 years
of screening to minimise confounding due to the possi-
ble effects of early disease affecting cholesterol [27].
Results
Data from 13,071 men were available for analysis, 6022
(46.1%) from the Collaborative Study and 7049 (53.9%)
from Renfrew/Paisley. Five Collaborative and nine
Renfrew/Paisley participants were lost to follow up, and
42 Collaborative and 55 Renfrew/Paisley participants
had missing cholesterol data. Twenty six individuals
who participated in both the studies were excluded from
the Renfrew/Paisley study. Eight individuals diagnosed
with PC in the first 5 years of screening were also
excluded from the analysis. Our final sample therefore
comprised 12,926 men followed-up for a total of
293,284 person-years. The median follow-up period was
24 years, maximum 37 years. Median age was 51 years
at the time of screening (range, 21-75 years).
Baseline and outcome characteristics for the study are
s h o w ni nT a b l e1 .S i xh u n d r e da n df i f t ym e nw i t hP C
were identified. Among 307 cancers that occurred from
1997 onward (when Gleason score was included in can-
cer registry data), 119 (38.8%) were high grade (Gleason
score≥8), 57 (18.6%) were intermediate grade (Gleason =
7), 64 (20.8%) low grade (Gleason≤6) and the remaining
67 (21.8%) were of unknown Gleason score. Increasing
weight and BMI were positively associated with choles-
terol while current smoking and lower socioeconomic
status were inversely associated with cholesterol (data
not shown). Mean plasma cholesterol level did not differ
(p = 0.27) between men who were diagnosed with pros-
tate cancer (5.85 mmol/l ± 0.99) and those who
remained free from it (5.87 mmol/l ± 0.99). The mean
time between screening (plasma cholesterol measure-
ment) and the prostate cancer diagnosis was 22.9 (SD
7.84) years.
Using age as the time-scale we found no convincing
association between cholesterol and overall hazard of
PC, nor any consistent relationship within low and
intermediate grade disease (Table 2). However, the
hazard increased consistently from the lowest to the
second highest quintile of cholesterol among high
grade disease (Gleason score ≥ 8). We explored the
relationship between cholesterol and high grade disease
further in Table 3. After adjustment for BMI, smoking
and socioeconomic status, a progressive increase in
risk of high grade prostate remained between the low-
est and second highest quintiles of cholesterol. This is
more clearly shown in Figure 1, in which the smoothed
hazard of the most aggressive PCs (Gleason score≥8)
increased with increasing cholesterol and then
declined. As no significant association was observed
between the highest quintile of cholesterol and risk of
high grade disease, we combined the last two quintiles
to further investigate the association. We observed sig-
nificantly higher risk (HR 1.88, 95 CI 1.08-3.27, p-
value 0.03) of developing high grade disease among
men in the highest cholesterol category (combination
of 4
th and 5
th quintile). Furthermore, we also investi-
gated the association between cholesterol and risk of
high grade disease using the clinical cut points. Men in
the higher cholesterol group (≥ 6.21 mmols/l) had sig-
nificantly increased risk of developing high grade dis-
ease (1.75, 95% CI 1.03-2.97, p value 0.036) compared
to the desirable cholesterol group (< 5.1 mmols/l) after
adjustment for BMI, smoking and socioeconomic sta-
tus (data not shown).
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N = 12,926
Controls Prostate cancer cases Gleason < 7 Gleason = 7 Gleason 8-10 Unknown Gleason
Sample Size 12,276 650 64 57 119 67
Number of Deaths%(n) 76.4 (9,384) 81.1 (527) 51.6 (33) 52.6 (30) 73.9 (88) 82.1 (55)
Cholesterol quintiles, mmol/L,%(n)
< 5.05 94.9 (2,589) 5.1 (138) 24.6 (15) 21.3 (13) 27.9 (17) 26.2 (16)
5.06 - < 5.57 95.3 (2,471) 4.7 (121) 17.7 (9) 13.7 (7) 37.2 (19) 31.4 (16)
5.58 - < 6.09 94.9 (2,676) 5.1 (145) 26.1 (17) 12.3 (8) 46.2 (30) 15.4 (10)
6.1 - < 6.69 94.5 (2,161) 5.5 (125) 16.9 (12) 18.3 (13) 46.5 (33) 18.3 (13)
≥6.7 95.2 (2,379) 4.8 (121) 18.6 (11) 27.1 (16) 33.9 (20) 20.3 (12)
Mean Age (s.d.) 51.1 (7.2) 51.7 (6.8) 46.9 (6.8) 46.7 (6.3) 49.2 (6.3) 50.7 (6.5)
Mean Height (s.d.) 171.1 (7.1) 172.0 (6.9) 172.6 (7.3) 173.3 (6.1) 172.3 (6.5) 172.6 (7.3)
Mean Weight (s.d.) 74.8 (11.1) 75.9 (10.4) 75.7 (10.8) 76.0 (9.0) 74.9 (9.5) 76.3 (9.6)
Height (cm),%(n)
≤165.1 95.9 (2,770) 4.1 (120) 24.5 (12) 14.3 (7) 34.7 (17) 26.5 (13)
165.2-170 95.3 (2,551) 4.7 (126) 19.1 (9) 12.8 (6) 49.0 (23) 19.1 (9)
170.1-172.72 95.0 (2,321) 5.0 (121) 19.7 (13) 27.3 (18) 33.3 (22) 19.7 (13)
172.73-177.8 94.3 (2,745) 5.7 (165) 19.0 (16) 17.9 (15) 42.9 (36) 20.2 (17)
≥177.9 94.1 (1,887) 5.9 (118) 23.0 (14) 18.0 (11) 34.4 (21) 24.6 (15)
Missing 0.0 (2) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Mean BMI (s.d.) 25.5 (3.3) 25.6 (3.0) 25.4 (3.0) 25.3 (2.7) 25.2 (3.0) 25.6 (3.0)
BMI (kg m
-2),%(n)
< 25 (Under & Desirable weight ) 95.2 (5,499) 4.8 (279) 20.8 (31) 17.5 (26) 40.9 (61) 20.8 (31)
25 - < 30 (Overweight) 94.7 (5,729) 5.3 (320) 21.9 (30) 19.7 (27) 34.3 (47) 24.1 (33)
≥30 (Obese) 95.4 (1,046) 4.6 (51) 14.3 (3) 19.0 (4) 52.4 (11) 14.3 (3)
Missing 0.0 (2) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Smoking,%(n)
Never smoker 93.3 (2,093) 6.7 (149) 22.8 (18) 19.0 (15) 39.2 (31) 19.0 (15)
Smoker 96.1 (7,253) 3.9 (294) 18.3 (24) 17.6 (23) 39.7 (52) 24.4 (32)
Ex-smoker 93.4 (2,929) 6.6 (207) 22.7 (22) 19.6 (19) 37.1 (36) 20.6 (20)
Missing 0.0 (1) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Social Class,%(n)
I&II 94.2 (3,090) 5.8 (190) 16.3 (16) 23.5 (23) 38.8 (38) 21.4 (21)
IIIN 94.4 (1,810) 5.6 (108) 27.8 (15) 11.1 (6) 40.7 (22) 20.4 (11)
IIIM 95.3 (4,247) 4.7 (208) 18.1 (15) 19.3 (16) 37.3 (31) 25.3 (21)
IV&V 95.8 (3,057) 4.2 (135) 25.0 (17) 16.2 (11) 38.2 (26) 20.6 (14)
Missing 88.9 (72) 11.1 (9) 25.0 (1) 25.0 (1) 50.0 (2) 0.0 (0)
Table 2 Unadjusted hazard ratios and 95% CI for overall and Gleason-specific prostate cancer by cholesterol quintiles
among Midspan subjects who survived until 1
st January 1997. N = 6486.
All Prostate cancer Gleason < 7 Gleason 7 Gleason ≥8 Unknown
Cholesterol
(mmol/L)
quintiles
(n) Hazard
Ratio (95%
CI)
% (n) Hazard Ratio
(95%CI)
% (n) Hazard Ratio
(95%CI)
% (n) Hazard
Ratio (95%
CI)
% (n) Hazard
Ratio (95%
CI)
< 5.05 1,384 (61) 1 24.6 (15) 1 21.3 (13) 1 27.9 (17) 1 26.2 (16) 1
5.06 - <
5.57
1,308 (51) 0.87 (0.60,
1.26)
17.6 (9) 0.62 (0.27,1.41) 13.7 (7) 0.54 (0.22,1.36) 37.3 (19) 1.18 (0.61,
2.27)
31.4 (16) 1.04 (0.52,
2.09)
5.58 - <
6.09
1,425 (65) 1.03 (0.72,
1.46)
26.2 (17) 1.1 (0.56,2.27) 12.3 (8) 0.59 (0.24,1.42) 26.2 (30) 1.70 (0.93,
3.07)
15.4 (10) 0.59 (0.27,
1.31)
6.1 - < 6.69 1,159 (71) 1.36 (0.97,
1.92)
16.9 (12) 0.96 (0.45,2.05) 18.3 (13) 1.14 (0.53,2.47) 46.5 (33) 2.28 (1.27,
4.10)
18.3 (13) 0.95 (0.46,
1.98)
≥6.7 1,210 (59) 1.09 (0.76,
1.57)
18.6 (11) 0.83 (0.38,1.81) 27.1 (16) 1.35 (0.65,2.81) 33.9 (20) 1.34 (0.70,
2.57)
20.3 (12) 0.85 (0.40,
1.80)
Univariate hazard ratios and 95% confidence intervals were estimated within a model employing age as time-scale
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association between cholesterol level and high grade
prostate cancer differed by BMI, however, no clear rela-
tionship emerged when using the desirable, overweight
and obese categories, due to smaller number of aggres-
sive PC cases in two highest cholesterol quintiles of
obese group (n = 7), so analysis was then stratified
based on the median BMI of the sample. There was no
evidence of an association between cholesterol level and
risk of high grade disease in men with BMIs lower than
25.3. However, among men with high BMI (≥ 25.3, med-
ian of the sample), those in the second highest choles-
terol quintile were significantly more likely to develop
high grade disease (HR 9.98, 95% CI 2.33-42.78, p value
0.002) after adjustments for socioeconomic status and
smoking status (data not shown). Similarly among men
with higher BMI, when we combined the two highest
cholesterol quintiles, those in the highest category had
seven times higher risk of developing high grade disease
compared to the lowest cholesterol group. We also
examined the interaction between cholesterol and BMI
within multivariate model, however, no significant inter-
action was observed between BMI and cholesterol (p for
interaction 0.86). We also noted a progressive increase
in risk of all PCs with increasing height in univariate
analysis, for this reason we also ran a multivariate
model using height instead of BMI to examine any con-
founding effect, however, the associations of cholesterol
and height with PC incidence remained consistent after
adjusting for smoking and socioeconomic status (Table
3).
Discussion
We found that plasma cholesterol was positively asso-
ciated with increased risk of aggressive prostate cancer
but not with overall risk of developing the disease in
this population-based prospective cohort study. Our
findings are consistent with others reported on United
States populations [15-17]. Similarly, data from the
Swedish Apolipoprotein Mortality Risk (AMORIS) study
Table 3 Multivariate hazard ratios (HR) for all prostate cancers and those with Gleason grade ≥ 8 by cholesterol
quintiles
All Prostate Cancers Prostate cancers Gleason ≥ 8
Baseline Sample From 1st January 1997
% n Hazard Ratio (95% CI) % n Hazard Ratio (95% CI)
Cholesterol (mmol/L) quintiles
< 5.05 5.1 (138) 1 1.2 (17) 1
5.06 - < 5.57 4.7 (121) 0.89 (0.70, 1.14) 1.5 (19) 1.18 (0.62, 2.28)
5.58 - < 6.09 5.1 (145) 0.95 (0.75, 1.21) 2.1 (30) 1.72 (0.95, 3.13)
6.1 - < 6.69 5.5 (125) 1.01 (0.79, 1.29) 2.8 (33) 2.34 (1.30, 4.23)
≥6.7 4.8 (121) 0.95 (0.74, 1.22) 1.7 (20) 1.40 (0.73, 2.71)
BMI (kg m
-2)
< 25 (Under & Desirable weight) 4.8 (279) 1 2.1 (61) 1
25 - < 30 (Overweight) 5.3 (320) 1.02 (0.86, 1.20) 1.5 (47) 0.69 (0.47, 1.02)
≥30 (Obese) 4.6 (51) 1.03 (0.77, 1.40) 2.3 (11) 1.18 (0.62, 2.27)
Smoking
Never smoker 6.6 (149) 1 2.1 (31) 1
Smoker 3.9 (294) 0.90 (0.73, 1.09) 1.6 (52) 0.92 (0.59, 1.45)
Ex-smoker 6.6 (207) 1.03 (0.77, 1.40) 2.1 (36) 1.06 (0.65, 1.72)
Social Class
I&II 5.8 (190) 1 1.9 (38) 1
IIIN 5.6 (108) 1.10 (0.87, 1.40) 2.2 (22) 1.21 (0.71, 2.05)
IIIM 4.7 (217) 1.03 (0.85, 1.26) 1.6 (33) 0.95 (0.59, 1.53)
IV&V 4.2 (135) 0.91 (0.73, 1.14) 1.9 (26) 1.15 (0.69, 1.92)
Height (cm)
≤165.1 4.9 (120) 1 1.8 (17) 1
165.2-170 4.7 (126) 1.05 (0.82, 1.35) 1.8 (23) 1.27 1(0.68, 2.37)
170.1-172.72 4.2 (121) 1.11 (0.86, 1.43) 1.4 (22) 1.54 (0.61, 2.19)
172.73-177.8 7.5 (165) 1.27 (1.01, 1.61) 3.2 (36) 1.69 (0.94, 3.05)
≥177.9 4.3 (118) 1.35, (1.04 1.75) 1.3 (21) 1.32 (0.68, 2.55)
Multivariate hazard ratios and 95% CIs were obtained by using age as time-scale; all covariates were included in the model except height. Estimates for height
were obtained by replacing the BMI with height
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Page 5 of 8reported no evidence of a relationship between hyperch-
olesterolemia and overall prostate cancer risk [28]. How-
ever, a large study of male Finnish smokers, reported a
positive association between increasing total cholesterol
level and overall risk of prostate cancer particularly
advanced stage prostate cancer [29]. The association
further strengthened when they restricted the analysis to
the cases diagnosed after 10 years from the baseline.
However, this study did not find any association
between aggressive disease, which may be because Glea-
son score was only available for 25% of the prostate can-
cer patients [29].
Several underlying mechanisms by which cholesterol
and prostate carcinogenesis may be linked have been
proposed. Prostate cancer cells tend to over accumulate
cholesterol in their cell membrane, forming large lipid
rafts which in the cancer cells may facilitate pro-carci-
nogenic cell signalling [29-31]. Moreover, several other
pathways which are considered vital in carcinogenesis,
such as sonic hedgehog and Akt pathways, are also cho-
lesterol sensitive [32,33]. Thus, having a lower choles-
terol level may inhibit these pro-carcinogenic activities
in the prostate cells.
Generally, an association has been reported between
low cholesterol and increased risk of many cancer types
and their associated mortality [9,11,12] which has been
ascribed to reverse causality; that is, early undiagnosed
cancers lead to behavioural and physiological changes
that reduce plasma cholesterol. The longer period
between baseline cholesterol assay and diagnosis in our
study (about 21 years for grade-specific analyses) com-
pared to others suggests that reverse causality is unlikely
to have been responsible for the observed association.
Moreover, any such effect would have been expected to
attenuate rather than exaggerate the association.
The potential clinical implications of our findings are
that increasing obesity and associated dyslipidemia may
have been responsible for the increasing incidence of
prostate cancer and that modifying cholesterol may
reduce incidence of more aggressive disease. The evi-
dence that statins may reduce prostate cancer incidence
remains equivocal. Two meta-analyses and a subsequent
cohort study did not find any relationship between sta-
tin use and prostate cancer [34-36]. However, Platz and
Jacobs found associations between statin use and lower
risk of advanced prostate cancer only and suggested that
plausible biological mechanisms may existed, for exam-
ple 3-hydroxy-3-methylglutaryl (HMG) coenzyme A
reductase inhibition may reduce prostate cancer cell sur-
vival by interfering with membrane-associated signalling.
0
1
2
3
4
5
r
e
l
a
t
i
v
e
 
h
a
z
a
r
d
45678
cholesterol (mmol/l)
Figure 1 Functional form of the association of cholesterol with the relative hazard of Gleason 8 to 10 prostate cancers estimated in a
Cox proportional hazards model using age as the time axis. The function was fitted using restricted cubic splines with three knots (X). The
function was standardized such that the HR was 1 at the mean cholesterol level of the lowest quintile. Dotted lines indicate the 95% confidence
intervals.
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effects of statins on prostate cancer, the most effective
means of reducing incidence of the disease may there-
fore be through effective weight management.
Our research is based on one of the largest population
based prospective studies in the United Kingdom and
used cancer incidence data for the grade-specific ana-
lyses, rather than death records for cancer outcomes.
Mortality data are a product of both incidence and case
fatality, and do not allow risk factors to be individually
differentiated. Furthermore, high cholesterol may
increase the risk of death from other causes in prostate
cancer patients and not necessarily be a causal factor for
prostate cancer itself. Our study has larger numbers of
incident cancers (n = 650), longer follow up and lower
losses to follow up (0.1%) compared with earlier studies
[15,16]. However, our study has some weaknesses. The
number of cases with aggressive PC was smaller; this
may have influenced our results in some analyses. The
Midspan questionnaire lacked information on family
history of PC, prostate specific antigen screening and
u s eo fs t a t i n s .W eu s e dp l a s m at o t a lc h o l e s t e r o ll e v e l
because other measures of cholesterol, such as lipopro-
tein fractions (high and low density lipoproteins), were
not available. Prostate specific antigen and disease stage
data were not available which could be used to stratify
the analyses based on localised and metastatic prostate
cancer. The mean age at prostate cancer diagnosis is
high and a large proportion of men are likely to die
before diagnosis. The risk estimates we present might
therefore have been affected by differential competing
mortality risks. However, Cancer Registry data include
Death Certificate Only diagnoses–and may have
included, prostate cancers detected at post-mortem–that
will attenuate such survival biases. The proportion of
men who develop PC is higher among those who do not
smoke, have a desirable BMI and are taller. The higher
proportion of PC among these men results from those
factors which confer a survival advantage. They live
longer and therefore experience a longer risk time.
However, the observation that height is associated with
PC does raise the question whether some of those char-
acteristics which promote longevity, are also associated
with an increased risk of PC or whether such associa-
tions spuriously result from the influence of competing
risk. Height is linked with development of many adult
cancers [37-39], a meta-analysis of 58 studies also sug-
gested that height is positively associated with incident
prostate cancer with stronger effect for advance stage
and aggressive disease [40]. There is some suggestion
that height might be confounded by the socioeconomic
status of the individual, however in our study height was
associated with overall risk of prostate cancer indepen-
dent of socioeconomic status.
Cholesterol, height and obesity are related to mortality
from cardiovascular disease [27,41-43] and early death
from cardiovascular disease may be an important con-
sideration. One possible scenario is that early cardiovas-
cular disease mortality exhausts the pool of those men
who would otherwise be susceptible to PC in later life,
consequently systematic selection of more resilient indi-
vidual may take place (men with low risk of PC but
with high levels of traditional cardiovascular risk fac-
tors). This potentially could explain the positive associa-
tion between height and overall incident PC, but would
fail to explain the association between cholesterol and
aggressive PC, which we report. A further consideration
is detection bias and whether some groups are more
likely to report their symptoms or have frequent medical
examinations.
Further research is needed on cancer registry data to
determine whether high-grade prostate cancer has dif-
ferentially increased following increases in metabolic
factors associated with hypercholesterolaemia. Longer-
term follow-up of clinical trials of statins is also
required, with exclusions of early tumours to minimise
the potential effects of “reverse causality” on any
association.
Conclusion
In this population-based cohort study, high cholesterol
level was associated with increased risk of aggressive
prostate cancer; these findings support the results from
earlier studies. Further research is needed to describe
temporal trends in grade-specific prostate cancer and to
understand the biological mechanisms by which choles-
terol and prostate cancer are associated.
Acknowledgements
The study received no external funding. Authors were funded by, viz:
University of Glasgow (PM, HL, DSM), Higher Education Commission of
Pakistan (KS), NHS Greater Glasgow and Clyde (KQ), and NHS Health
Scotland (CH). Victor Hawthorne carried out the original Midspan studies.
Pauline MacKinnon is the Midspan administrator.
Author details
1Institute of Health & Wellbeing, Public Health, University of Glasgow, 1
Lilybank Gardens, Glasgow G12 8RZ, UK.
2West of Scotland Cancer
Surveillance Unit, University of Glasgow, 1 Lilybank Gardens, Glasgow G12
8RZ, UK.
3Urology Department, Gartnavel General Hospital, 1053 Great
Western Road, Glasgow G12 0YN, UK.
4Beatson Institute for Cancer Research,
Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.
Authors’ contributions
All authors designed the study; KS and PM carried out statistical analyses; all
authors contributed to interpreting the results; KS, PM and DSM drafted the
manuscript; all authors saw and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 September 2011 Accepted: 19 January 2012
Published: 19 January 2012
Shafique et al. BMC Cancer 2012, 12:25
http://www.biomedcentral.com/1471-2407/12/25
Page 7 of 8References
1. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A: Prostate cancer
incidence and mortality trends in 37 European countries: an overview.
Eur J Cancer 2010, 46:3040-3052.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al: Cancer statistics,
2008. CA Cancer J Clin 2008, 58:71-96.
3. Johns LE, Houlston RS: A systematic review and meta-analysis of familial
prostate cancer risk. BJU Int 2003, 91:789-794.
4. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD: Age
and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996,
30:138-144.
5. Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al:
The risk of prostate cancer amongst black men in the United Kingdom:
the PROCESS cohort study. Eur Urol 2008, 53:99-105.
6. Baade PD, Youlden DR, Krnjacki LJ: International epidemiology of prostate
cancer: geographical distribution and secular trends. Mol Nutr Food Res
2009, 53:171-184.
7. White RM: On the occurrence of crystals in tumours. J Pathol Bacteriol
1909, 13:3-10.
8. Bravi F, Scotti L, Bosetti C, Talamini R, Negri E, Montella M, et al: Self-
reported history of hypercholesterolaemia and gallstones and the risk of
prostate cancer. Ann of Oncol 2006, 17:1014-1017.
9. Hiatt RA, Fireman BH: Serum cholesterol and the incidence of cancer in a
large cohort. J Chr Dis 1986, 39:861-870.
10. Kark JD, Smith AH, Hames CG: Serum retinol and the inverse relationship
between serum cholesterol and cancer. Br Med J 1982, 284:152-154.
11. Knekt P, Reunanen A, Aromaa A, Heliovaara M, Hakulinen T, Hakama M:
Serum cholesterol and risk of cancer in a cohort of 39,000 men and
women. J Clin Epidemiol 1988, 41:519-530.
12. Davey Smith G, Shipley MJ, Marmot MG, Rose G: Plasma cholesterol
concentration and mortality. The Whitehall Study. JAMA 1992, 267:70-76.
13. Thompson MM, Garland C, Barrett-Connor E, Khaw K-T, Friedlander NJ,
Wingard DL: Heart disease risk factors, diabetes, and prostatic cancer in
an adult community. Am J Epidemiol 1989, 129:511-517.
14. Batty GD, Kivimaki M, Clarke R, Davey Smith G, Shipley MJ: Modifiable risk
factors for prostate cancer mortality in London: forty years of follow-up
in the Whitehall study. Canc Causes Contr 2011, 22:311-318.
15. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA: Association between plasma
total cholesterol concentration and incident prostate cancer in the CLUE
II cohort. Canc Causes Contr 2010, 21:61-68.
16. Platz EA, Clinton SK, Giovannucci E: Association between plasma
cholesterol and prostate cancer in the PSA era. Int J Cancer 2008,
123:1693-1698.
17. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, et al: Men
with low serum cholesterol have a lower risk of high-grade prostate
cancer in the placebo arm of the prostate cancer prevention trial. Cancer
Epidemiol Biomarkers Prev 2009, 18:2807-2813.
18. Hart CL, MacKinnon PL, Watt GC, Upton MN, McConnachie A, Hole DJ, et al:
The Midspan studies. Int J Epidemiol 2005, 34:28-34.
19. Davey Smith G, Hart C, Hole D, MacKinnon P, Gillis C, Watt G, et al:
Education and occupational social class: Which is the more important
indicator of mortality risk? J Epidemiol Community Health 1998, 52:153-160.
20. Hawthorne VM, Watt GC, Hart CL, Hole DJ, Davey Smith G, Gillis CR:
Cardiorespiratory disease in men and women in urban Scotland:
baseline characteristics of the Renfrew/Paisley (midspan) study
population. Scott Med J 1995, 40:102-107.
21. Resnick MJ, Canter DJ, Guzzo TJ, Brucker BM, Bergey M, Sonnad SS, et al:
Does race affect postoperative outcomes in patients with low-risk
prostate cancer who undergo radical prostatectomy? Urology 2009,
73:620-623.
22. General Register Office: Classification of Occupation London: HMSO; 1966,
1-136.
23. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC: Risk factors for
prostate cancer incidence and progression in the health professionals
follow-up study. Int J Cancer 2007, 121:1571-1578.
24. Hart CL, Batty GD, Morrison DS, Mitchell RJ, Davey Smith G: Obesity,
overweight and liver disease in the Midspan prospective cohort studies.
Int J Obesity 2010, 34:1051-1059.
25. Korn EL, Graubard BI, Midthune D: Time-to-event analysis of longitudinal
follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997,
145:72-80.
26. National Heart, Lung and Blood Institute: Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III). Bethesda, MD: National Heart, Lung, and Blood Institute
of Health NIH publication; 2002, 02-5215 accessed on 29th Nov, 2011.
27. Lawlor DA, Hart CL, Hole DJ, Davey Smith G: Reverse causality and
confounding and the associations of overweight and obesity with
mortality. Obesity (Silver Spring) 2006, 14:2294-2304.
28. Van HM, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N, et al:
Prostate cancer risk in the Swedish AMORIS study: the interplay among
triglycerides, total cholesterol, and glucose. Cancer 2011, 117:2086-95.
29. Mondul AM, Weinstein SJ, Virtamo J, Albanes D: Serum total and HDL
cholesterol and risk of prostate cancer. Canc Causes Contr 2011,
22:1545-1552.
30. Freeman MR, Solomon KR: Cholesterol and prostate cancer. J Cell Biochem
2004, 91:54-69.
31. Hager MH, Solomon KR, Freeman MR: The role of cholesterol in prostate
cancer. Curr Opin Clin Nutr Metab Care 2006, 9:379-385.
32. Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS, Hong SJ: Cholesterol level of
lipid raft microdomains regulates apoptotic cell death in prostate cancer
cells through EGFR-mediated Akt and ERK signal transduction. Prostate
2007, 67:1061-1069.
33. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR: Cholesterol-rich lipid
rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res
2002, 62:2227-2231.
34. Boudreau DM, Yu O, Buist DS, Miglioretti DL: Statin use and prostate
cancer risk in a large population-based setting. Canc Causes Contr 2008,
19:767-774.
35. Browning DR, Martin RM: Statins and risk of cancer: a systematic review
and metaanalysis. Int J Cancer 2007, 120:833-843.
36. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM: Statins and cancer
risk: a meta-analysis. JAMA 2006, 295:74-80.
37. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V: Height and
cancer incidence in the Million Women Study: prospective cohort, and
meta-analysis of prospective studies of height and total cancer risk.
Lancet Oncol 2011, 12:785-794.
38. Renehan AG: Height and cancer: consistent links, but mechanisms
unclear. Lancet Oncol 2011, 12:716-717.
39. Schouten LJ, Rivera C, Hunter DJ, Spiegelman D, Adami HO, Arslan A, et al:
Height, body mass index, and ovarian cancer: a pooled analysis of 12
cohort studies. Cancer Epidemiol Biomarkers Prev 2008, 17:902-912.
40. Zuccolo L, Harris R, Gunnell D, Oliver S, Lane JA, Davis M, et al: Height and
prostate cancer risk: a large nested case-control study (ProtecT) and
meta-analysis. Cancer Epidemiol Biomarkers Prev 2008, 17:2325-2336.
41. Neaton JD, Kuller LH, Wentworth D, Borhani NO: Total and cardiovascular
mortality in relation to cigarette smoking, serum cholesterol
concentration, and diastolic blood pressure among black and white
males followed up for five years. Am Heart J 1984, 108:759-769.
42. Strandberg TE: Inverse relation between height and cardiovascular
mortality in men during 30-year follow-up. Am J Cardiol 1997, 80:349-350.
43. Turley ML, Tobias M, Lawes CM, Stefanogiannis N, Vander HS, Mhurchu CN,
et al: Cardiovascular mortality attributable to high blood cholesterol in
New Zealand. Aust N Z J Public Health 2006, 30:252-257.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/12/25/prepub
doi:10.1186/1471-2407-12-25
Cite this article as: Shafique et al.: Cholesterol and the risk of grade-
specific prostate cancer incidence: evidence from two large prospective
cohort studies with up to 37 years’ follow up. BMC Cancer 2012 12:25.
Shafique et al. BMC Cancer 2012, 12:25
http://www.biomedcentral.com/1471-2407/12/25
Page 8 of 8